{"title":"The Value of LC-MS/MS in Apparent Bilateral Aldosterone Suppression in Adrenal Venous Sampling for Primary Aldosteronism.","authors":"Wei Li, Qixin Zhou, Yifan He, Wenwen He, Ying Song, Jinbo Hu, Yue Wang, Ting Luo, Qifu Li, Shumin Yang","doi":"10.1210/clinem/dgae891","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Adrenal venous sampling (AVS) is recommended for subtyping primary aldosteronism (PA), however, it is unreliable when apparent bilateral aldosterone suppression (ABAS) occurs, defined as aldosterone/cortisol ratio in the adrenal vein being bilaterally lower than that in the inferior vena cava. The value of Liquid chromatography-tandem mass spectrometry (LC-MS/MS) in PA subtyping when ABAS occurs is unclear.</p><p><strong>Objective: </strong>To determine whether LC-MS/MS can reduce the occurrence of ABAS and misdiagnosis of PA subtyping.</p><p><strong>Design, setting, participants and main outcome: </strong>Aldosterone and cortisol in AVS samples from 219 patients with PA were measured by LC-MS/MS and immunoassay. Then ABAS occurrence and misdiagnosis rate of PA subtyping were calculated.</p><p><strong>Results: </strong>Among 219 patients with PA, 111 and 60 received non-ACTH and ACTH-stimulated AVS, respectively, and 48 received both. In unstimulated AVS, LC-MS/MS reduced the ABAS occurrence compared to immunoassay [10.7% (17/159) vs. 3.1% (5/159)]. Among 159 patients with unstimulated AVS, there were 77 patients who had final subtyping diagnosis based on postoperative outcomes. The misdiagnosis rate of immunoassay and LC-MS/MS was 10.4% (8/77) and 9.1% (7/77), respectively. However, the misdiagnosis were more common in patients with ABAS than in those without ABAS. For immunoassay, five out of six ABAS patients were misdiagnosed, while 3/71 non-ABAS patients were misdiagnosed. For LC MS/MS, only one ABAS patient had follow-up outcome and he was misdiagnosed, while 6/76 non-ABAS patients were misdiagnosed. Similar results were found in ACTH-stimulated AVS.</p><p><strong>Conclusion: </strong>LC-MS/MS measurement of aldosterone and cortisol is a new resolution when ABAS occurs.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1210/clinem/dgae891","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Adrenal venous sampling (AVS) is recommended for subtyping primary aldosteronism (PA), however, it is unreliable when apparent bilateral aldosterone suppression (ABAS) occurs, defined as aldosterone/cortisol ratio in the adrenal vein being bilaterally lower than that in the inferior vena cava. The value of Liquid chromatography-tandem mass spectrometry (LC-MS/MS) in PA subtyping when ABAS occurs is unclear.
Objective: To determine whether LC-MS/MS can reduce the occurrence of ABAS and misdiagnosis of PA subtyping.
Design, setting, participants and main outcome: Aldosterone and cortisol in AVS samples from 219 patients with PA were measured by LC-MS/MS and immunoassay. Then ABAS occurrence and misdiagnosis rate of PA subtyping were calculated.
Results: Among 219 patients with PA, 111 and 60 received non-ACTH and ACTH-stimulated AVS, respectively, and 48 received both. In unstimulated AVS, LC-MS/MS reduced the ABAS occurrence compared to immunoassay [10.7% (17/159) vs. 3.1% (5/159)]. Among 159 patients with unstimulated AVS, there were 77 patients who had final subtyping diagnosis based on postoperative outcomes. The misdiagnosis rate of immunoassay and LC-MS/MS was 10.4% (8/77) and 9.1% (7/77), respectively. However, the misdiagnosis were more common in patients with ABAS than in those without ABAS. For immunoassay, five out of six ABAS patients were misdiagnosed, while 3/71 non-ABAS patients were misdiagnosed. For LC MS/MS, only one ABAS patient had follow-up outcome and he was misdiagnosed, while 6/76 non-ABAS patients were misdiagnosed. Similar results were found in ACTH-stimulated AVS.
Conclusion: LC-MS/MS measurement of aldosterone and cortisol is a new resolution when ABAS occurs.
期刊介绍:
The Journal of Clinical Endocrinology & Metabolism is the world"s leading peer-reviewed journal for endocrine clinical research and cutting edge clinical practice reviews. Each issue provides the latest in-depth coverage of new developments enhancing our understanding, diagnosis and treatment of endocrine and metabolic disorders. Regular features of special interest to endocrine consultants include clinical trials, clinical reviews, clinical practice guidelines, case seminars, and controversies in clinical endocrinology, as well as original reports of the most important advances in patient-oriented endocrine and metabolic research. According to the latest Thomson Reuters Journal Citation Report, JCE&M articles were cited 64,185 times in 2008.